Clinical Trial Search

Primary: Percent Changes in Endothelial Function as Measured by Flow Mediated Dilation by 2D Doppler Ultrasound on Day 2 — 2; 7 percentage of change

Primary: Cerebral Blood Flow — 1.7; 1.3 percentage of signal intensity change

Primary: Hypoglycemia Incidence — 53; 10 participants — p=<0.001

Primary: Number of Participants With Hypoglycemia (Blood Sugar Level <70 mg/dl — 11 Participants

Primary: Psychomotor Speed — 48.7; 56.6 score on a scale

Primary: Changes in Platelet Activation Marker Adenosin Diphosphate (%) — 63; 64.4; 64.4; 61.1 percentage of ADP

Primary: Proportion of Participants With Captured Hypoglycaemia — 3 Participants

Primary: Correlation Between HbA1c Values at Week 12 and Hypoglycemia Scores — -0.1215 Correlation coefficient — p=0.0002

Primary: Number of Participants Experiencing Hypoglycemic Episodes in the 6 Months Prior to Enrollment — 305 Participants

Primary: Insulin Sensitivity — 3.37*10^-4 1/min per uU/mL

Primary: Total and First Phase of Insulin Secretion (Insulinogenic Index and Stumvoll Index) After 90 Days — 0.41; 0.23; 1135.7; 309.0 index

Primary: Number of Participants Achieving Hemoglobin A1C (HbA1C) <7% — 378 participants

Primary: Fasting Plasma Glucose — 77.4; 77.7 mmol/L

Primary: Percentage of Time Spent in Hyperglycemia > 180 mg/dL — 35.47; 35.25 percentage of time spent > 180mg/dL

Primary: Δ Mean AUC (Area Under the Curve) Plasma [Glucose] — -17.7; 54.9 mmol.min.L-1

Primary: The Frequency of Hypoglycaemic Episodes With Sitagliptin vs Placebo Treatment. — 5.35; 5.72 Hypoglycaemic episodes

Primary: Maximum Epinephrine Response (LBGI Groups) — 495; 217 pg/ml

Primary: Normalization of Glucose Levels — 9; 2; 4 Participants — p=.035

Primary: Glucagon (pg/mL) — 76; 74; 53; 56 pg/mL

Primary: Hemoglobin A1C at 4 Weeks — 10.5; 11.1 percentage of glycosylated hemoglobin

Primary: The Percentage Change in HbA1c Level From Baseline to 12 Weeks — -11.1; 0.0 percentage change

Primary: Hospital Length of Stay — 7; 8 days

Primary: Recovery Time From Hypoglycemia to Euglycemia — 74.49; 88.90; 109.81 Minutes

Primary: Frequency of Eating in Response to Cravings (Primary Mechanistic Outcome) — -20.39; -25.27 % of EMAs with craving related eating

Primary: Self-reported Severe Hypoglycemia — 99; 99; 19; 13 Participants — p=0.27

Primary: Mean POC Glucose Level Between Groups — 225; 266 mg/dl

Primary: Fear of Hypoglycemia — 54.3; 58.7; 35.29; 49.0 units on a scale

Primary: Number of Participants With Composite Neonatal Morbidity — 149; 163; 62; 55 Participants — p=0.14

Primary: Type 2 Diabetes Blood Glucose Time in Range (70-180 mg/dL) — 25.31; 19.89; 26.04 percentage of time during CGM use — p=0.1460

Primary: Hemoglobin A1c — -1.3; -0.4 HbA1c, %